BOSTON SCIENTIFIC CORP (BSX): Results of Operations and Financial Condition
BOSTON SCIENTIFIC CORP (BSX) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE Boston Scientific announces results for second quarter 2026 Marlborough, Mass. (July 29, 2026) -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.442 billion during the second quarter of 2026, growing 7.5 percent on a reported basis and 7
How this was made
The 30-second read
Why it matters
Traders can reprice BSX based on the updated FY net sales growth range (reported 5.5% to 6.5%, organic 5% to 6%) and adjusted EPS range ($3.28 to $3.32), plus the Q3 net sales and adjusted EPS guidance. Additional near-term catalysts include completion of a $2B accelerated share repurchase, $1.5B investment for a ~34% equity stake in MiRus, FDA 510(k) clearance for TruSelect 2.6 Microcatheter, and late-breaking clinical trial data for FARAPULSE and FARAFLEX programs.
Market read
This is a primary earnings and guidance update with specific numeric ranges, making it directly tradable for both short-term positioning and near-term expectation setting.
What to watch
Some growth is described as operational/organic excluding FX and certain acquisitions/divestitures; investors may focus on whether underlying demand is truly broad-based versus mix and currency effects.
Boston Scientific generated net sales of $5.442 billion in the second quarter of 2026, up 7.5 percent on a reported basis, and reported GAAP EPS of $0.61 and adjusted EPS of $0.86.
Reported net sales grew 7.5 percent, both reportable segments grew, GAAP net income and adjusted EPS increased from the prior-year period, and adjusted EPS exceeded the company’s stated second-quarter guidance range. Third-quarter net sales growth guidance is below the reported second-quarter growth rate.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Net salesGAAP | $5.442 billion | – | 7.5 percent |
| Operational net sales growthnon-GAAP | 7.0 percent | – | – |
| Organic net sales growthnon-GAAP | 7.0 percent | – | – |
| GAAP net income attributable to Boston Scientific common stockholdersGAAP | $907 million | – | – |
| GAAP EPSGAAP | $0.61 per share | – | – |
| Adjusted EPSnon-GAAP | $0.86 per share | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| EndoscopyOperational and organic net sales growth were 7.0 %. | $ 793 million | – | 7.6 % |
| UrologyOperational and organic net sales growth were 0.8 %. | $ 684 million | – | 1.1 % |
| NeuromodulationOperational and organic net sales growth were 12.2 %. | $ 341 million | – | 12.7 % |
| MedSurgOperational and organic net sales growth were 5.4 %. | $ 1,818 million | – | 5.9 % |
| CardiovascularOperational and organic net sales growth were 7.8 %. | $ 3,624 million | – | 8.3 % |
| U.S.Operational net sales growth was 6.2 %. | $ 3,426 million | – | 6.2 % |
| EMEAOperational net sales growth was 4.2 %. | $ 932 million | – | 6.1 % |
| APACOperational net sales growth was 11.2 %. | $ 878 million | – | 11.2 % |
| LACAOperational net sales growth was 16.2 %. | $ 206 million | – | 22.4 % |
Full Year and Third Quarter 2026 outlook
- RevenueFull year 2026: approximately 5.5 to 6.5 percent on a reported basis and 5 to 6 percent on an organic basis. Third quarter of 2026: approximately 3 to 5 percent on a reported and organic basis.
- NoteFull year 2026 adjusted EPS, excluding certain charges (credits): $3.28 to $3.32.
- NoteThird quarter of 2026 adjusted EPS, excluding certain charges (credits): $0.80 to $0.82.
Capital returns
- Completed the previously announced $2 billion accelerated share repurchase program, repurchasing approximately 40 million shares.
What drove it
- Cardiovascular net sales grew 8.3 % on a reported basis and 7.8 % on an operational and organic basis.
- MedSurg net sales grew 5.9 % on a reported basis and 5.4 % on an operational and organic basis.
- APAC reported and operational net sales growth was 11.2 %.
- LACA reported net sales growth was 22.4 % and operational net sales growth was 16.2 %.
- The AVANT GUARD study met all safety and effectiveness endpoints and demonstrated statistical superiority of FARAPULSE PFA over anti-arrhythmic drugs with significantly higher primary effectiveness.
- The company commenced enrollment in the pivotal FARADIGM clinical trial and received U.S. Food and Drug Administration 510(k) clearance for the TruSelect™ 2.6 Microcatheter.
Concerns
- Urology reported net sales growth was 1.1 %, the lowest reported growth rate among the listed business lines.
- Third-quarter 2026 net sales growth guidance is approximately 3 to 5 percent on a reported and organic basis, compared with 7.5 percent reported net sales growth and 7.0 percent operational and organic net sales growth in the second quarter.
- The company did not provide a reconciliation of forward-looking adjusted EPS guidance to GAAP guidance because it cannot predict the impact of certain items with reasonable certainty.
What to watch
- Third-quarter 2026 reported and organic net sales growth guidance of approximately 3 to 5 percent.
- Third-quarter 2026 adjusted EPS guidance of $0.80 to $0.82.
- Full-year 2026 reported net sales growth guidance of approximately 5.5 to 6.5 percent and organic net sales growth guidance of 5 to 6 percent.
- Full-year 2026 adjusted EPS guidance of $3.28 to $3.32.
- Execution of the MiRus LLC investment, including the exclusive option to acquire the MiRus TAVR business.
- Progress of the FARADIGM pivotal clinical trial for the FARAFLEX Mapping and PFA Catheter.
Balance sheet and cash flow
- Invested $1.5 billion in MiRus LLC in return for an approximately 34% equity stake and exclusive option to acquire the MiRus TAVR business.
Analysis
Boston Scientific reported second-quarter net sales of $5.442 billion, up 7.5 percent on a reported basis and 7.0 percent on both an operational and organic basis compared with the prior-year period. GAAP net income attributable to Boston Scientific common stockholders was $907 million, compared with $797 million a year ago. GAAP EPS was $0.61 per share, compared with $0.53 per share, while adjusted EPS was $0.86 per share, compared with $0.75 per share.
Growth was broad across the two reportable segments. Cardiovascular produced $ 3,624 million of sales and grew 8.3 % on a reported basis, ahead of MedSurg, which generated $ 1,818 million and grew 5.9 %. Within MedSurg, Neuromodulation grew 12.7 %, Endoscopy grew 7.6 %, and Urology grew 1.1 %. Geographic performance was led by LACA at 22.4 % reported growth and APAC at 11.2 %, while U.S. sales grew 6.2 % and EMEA sales grew 6.1 %.
The company completed its previously announced $2 billion accelerated share repurchase program and repurchased approximately 40 million shares. It also invested $1.5 billion in MiRus LLC for an approximately 34% equity stake and an exclusive option to acquire the MiRus TAVR business. These actions place capital allocation alongside continued investment in cardiovascular technology and clinical development.
The company highlighted clinical and regulatory developments across its portfolio. The FRACTURE trial met its primary endpoints for the investigational SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter. The AVANT GUARD study met all safety and effectiveness endpoints and demonstrated statistical superiority of FARAPULSE PFA over anti-arrhythmic drugs, while enrollment began in the pivotal FARADIGM trial for FARAFLEX.
For the full year, Boston Scientific now estimates reported net sales growth of approximately 5.5 to 6.5 percent, organic growth of 5 to 6 percent, and adjusted EPS of $3.28 to $3.32. Third-quarter guidance calls for reported and organic net sales growth of approximately 3 to 5 percent and adjusted EPS of $0.80 to $0.82. The key reported issue is the lower third-quarter net sales growth range relative to second-quarter reported, operational and organic growth rates, alongside the absence of a forward GAAP EPS reconciliation.
Management, verbatim
Our team delivered a solid quarter while continuing to navigate a dynamic environment. We are focused on disciplined execution and prioritizing investments in our highest-impact opportunities, and we remain confident in Boston Scientific's long-term growth, anchored by our category leadership strategy and our commitment to meaningful innovation for patients and physicians.
Mike Mahoney, chairman and chief executive officer, Boston Scientific
Not in the filing
stated, not guessed- Gross profit and gross margin
- Operating income and operating margin
- Operating expenses
- Tax rate
- GAAP diluted weighted-average shares outstanding
- Adjusted net income
- Cash and cash equivalents
- Debt
- Operating cash flow
- Free cash flow
- Dividend information
- Prior-quarter financial comparisons
- Prior outlook section for comparison with actual results
- GAAP reconciliation for forward-looking adjusted EPS guidance
- Quantitative drivers of business-line and regional sales growth
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
The filing is an SEC Form 8-K for Item 2.02, attaching Boston Scientific’s Q2 2026 earnings release (EX-99.1) with financial results, segment/region growth, and updated full-year and third-quarter guidance.
Ticker impact
Boston Scientific reported Q2 2026 net sales of $5.442B (+7.5% reported) and raised full-year guidance to 5.5% to 6.5% reported growth.
Likely positive bias for BSX as guidance and adjusted EPS ranges are updated upward versus prior guidance framing, with additional catalysts from FDA clearance and trial readouts.
This is a primary-source earnings/guidance release (8-K with EX-99.1) containing specific financial results, updated FY adjusted EPS ($3.28 to $3.32) and net sales growth ranges, plus concrete corporate actions (accelerated repurchase) and regulatory clearance (510(k)).
Market effects
Medical device peers may see read-across on demand durability and procedure volumes, especially in cardiology and electrophysiology categories.
APAC and LACA show stronger reported growth (APAC 11.2%, LACA 22.4%), which may influence regional sales expectations for device distributors.
US-listed medtech sentiment could improve modestly if guidance credibility and capital return (repurchase) reinforce sector cash-flow narratives.
Counterpoint
Guidance is only modestly positive (FY reported net sales growth 5.5% to 6.5%), so upside may be limited if investors were expecting a larger acceleration.
Key entities
- issuerBoston Scientific Corporation
Reported Q2 2026 results, completed a $2B accelerated share repurchase, updated FY and Q3 guidance, and disclosed multiple device and clinical updates.
- private_companyMiRus LLC
Boston Scientific invested $1.5B for an approximately 34% equity stake and an exclusive option to acquire the MiRus TAVR business.
- regulatorU.S. Food and Drug Administration (FDA)
Provided 510(k) clearance for Boston Scientific’s TruSelect 2.6 Microcatheter.
